Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Aged
Aminoimidazole Carboxamide
/ analogs & derivatives
Apoptosis
/ drug effects
Azacitidine
/ therapeutic use
Cell Line, Tumor
Cell Proliferation
/ drug effects
Clinical Trials as Topic
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Myelodysplastic Syndromes
/ drug therapy
Recurrence
Ribonucleosides
/ pharmacology
Treatment Failure
AML
MDS
Phase I/II clinical trial
acadesine
apoptosis
azacitidine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 12 2019
25 12 2019
Historique:
received:
23
10
2019
revised:
22
11
2019
accepted:
28
11
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
7
5
2020
Statut:
epublish
Résumé
Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza
Identifiants
pubmed: 31881723
pii: ijms21010164
doi: 10.3390/ijms21010164
pmc: PMC6981810
pii:
doi:
Substances chimiques
Ribonucleosides
0
Aminoimidazole Carboxamide
360-97-4
acadesine
53IEF47846
Azacitidine
M801H13NRU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : Equipe Labellisée 2017-2019
Pays : International
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Nat Cell Biol. 2004 Dec;6(12):1221-8
pubmed: 15558033
Blood. 2010 Oct 21;116(16):3023-32
pubmed: 20664053
Blood. 2006 May 15;107(10):4109-14
pubmed: 16439685
Cell Cycle. 2011 Jul 15;10(14):2339-43
pubmed: 21654192
Blood. 2003 May 1;101(9):3674-80
pubmed: 12522004
Blood. 2011 Dec 8;118(24):6399-402
pubmed: 22021366
Leukemia. 2005 Feb;19(2):292-4
pubmed: 15549145
Cancer Chemother Pharmacol. 2013 Mar;71(3):581-91
pubmed: 23228986
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Leukemia. 2019 Jun;33(6):1501-1513
pubmed: 30607021
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Oncotarget. 2012 Apr;3(4):490-501
pubmed: 22577154
PLoS One. 2010 Feb 02;5(2):e9001
pubmed: 20126405
Cell Death Differ. 2012 Jan;19(1):87-95
pubmed: 22052193
Cell Death Differ. 2019 Mar;26(4):690-702
pubmed: 30728463
Cell. 2008 Jan 11;132(1):27-42
pubmed: 18191218
Oncotarget. 2014 Feb 15;5(3):726-39
pubmed: 24519895
Cell Death Differ. 2012 Jan;19(1):107-20
pubmed: 21760595
PLoS One. 2009 Nov 18;4(11):e7889
pubmed: 19924252
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Nat Rev Cancer. 2009 Aug;9(8):563-75
pubmed: 19629071
J Med Chem. 2017 Feb 23;60(4):1523-1533
pubmed: 28094938
Cell Cycle. 2010 Sep 1;9(17):3470-8
pubmed: 20703092
J Clin Oncol. 2011 Aug 20;29(24):3322-7
pubmed: 21788559
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Cell. 2006 Feb 10;124(3):471-84
pubmed: 16469695
Cell Death Differ. 2009 Jan;16(1):87-93
pubmed: 18806760